Date: 2017-04-13

Type of information: Licensing agreement

Compound: BMS-986089

Company: BMS (USA - NY) Roche (Switzerland)

Therapeutic area: Rare diseases - Genetic diseases - Neuromuscular diseases

Type agreement: licensing

Action mechanism: fusion protein. BMS-986089 is a novel fusion protein designed to suppress myostatin, a negative regulator of muscle growth. It is currently being investigated as a treatment option for patients with Duchenne muscular dystrophy, and has the potential for study in other neuromuscular disorders.

Disease: Duchenne muscular dystrophy (DMD)


  • • On April 13, 2017, BMS announced that it has entered into an  agreement to license BMS-986089, an anti-myostatin adnectin in development for Duchenne muscular dystrophy, to Roche.

Financial terms: Under the agreement to license BMS-986089, Roche will pay to BMS an upfront payment of $170 million with potential milestone payments of up to $205 million. BMS will receive tiered double-digit royalties if either asset is approved and commercialized. These agreements are subject to clearance under the Hart-Scott-Rodino Antitrust Improvements Act, and are expected to close in the second quarter of 2017.

Latest news:

Is general: Yes